Thyrotropin, Prolactin and Growth Hormone Response to Synthetic Thyrotropin-Releasing Hormone in Newborn Infants

Delitala, G.; Meloni, T; Masala, A.; Corti, Rachele

doi:10.1159/000241079

Cited by 8 publications

(6 citation statements)

References 8 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The basal GH levels measured in this study were lower than those reported by other investigators [2,6]. Al though we have no idea about the reason, it might be due to the difference of the kit used for GH titration, because some authors [3,10] reported values near ours even in the study on younger neonates.…”

Section: Discussioncontrasting

confidence: 78%

Growth Hormone Responses to Growth Hormone Releasing Factor in Neonates

Shimano¹,

Suzuki²,

Nagashima³

et al. 1985

Neonatology

View full text Add to dashboard Cite

The response of growth hormone (GH) to synthetic human growth hormone releasing factor (hGRF) administered intravenously was examined in 32 neonates aged 3–28 days. GH peaked at 30 min after hGRF administration and the mean ± SEM level of GH at maximal response was 66.4 ± 6.2 ng/ml. In the comparison between the neonates less than 7 days old and those more than 8 days old, between the neonates less than 37 weeks and those more than 38 weeks in gestational age, between the neonates under 2,500 g and those over 2,501 g in birth body weight, and between males and females, no significant statistical differences were observed.

show abstract

Section: Discussioncontrasting

confidence: 78%

Growth Hormone Responses to Growth Hormone Releasing Factor in Neonates

Shimano¹,

Suzuki²,

Nagashima³

et al. 1985

Neonatology

View full text Add to dashboard Cite

show abstract

“…The ele vated neonatal PRL levels arc thought to be due to increased estrogen levels, which stim ulate the turnover of the hypothalamic domapine pool and thereby influence PRL se cretion [11,23,35], The effect of MTC upon the release of PRL has been studied after acute and chronic therapy in adult humans [12,16] and children, and it was demon strated to produce similar alterations to those found in the present study [14], Our data suggest that MTC is a potent stimulus of PRL release already in the early neonatal period and it may be used to assess pituitary PRL reserve in the neonate as efficiently as the TRH test [7], In this study MTC produced no signifi cant alterations in serum levels of TSH, FT4 and Tv Scanlon et al [31 ] explained the lack of TSH release in response to MTC through the inhibitory effects of circulating thyroid hormones, because in hypothyroid patients with very low hormone levels there was a sig nificant TSH release after MTC administra tion. In contrast.…”

Section: Discussionsupporting

confidence: 69%

Effect of Metoclopramide Treatment on Thyrotropin and Prolactin Levels in Sick Neonates

Ruppert

Sulyok²,

Sarkany

et al. 1986

Neonatology

View full text Add to dashboard Cite

The present study was carried out to define whether dopaminergic mechanisms contribute to the regulation of thyrotropin (TSH) and prolactin PRL release in the immediate neonatal period. 14 full-term neonates with a mean birth weight of 3,240 g and a mean gestational age of 39.1 weeks were administered metoclopramide (MTC), a specific dopamine antagonist, in a dose of 0.1 mg/kg/day to treat delayed gastric emptying, regurgitation and abdominal distension. Prior to and after 3-day MTC administration, blood samples were taken to determine serum TSH and PRL levels using a radioimmunoassay method. It has been demonstrated that in response to MTC administration PRL increased significantly from 4,010 ± 383 to 5,478 ± 441 mU/1 (p < 0.01), while TSH showed only a tendency to rise independent of the pretreatment hormone levels (from 2.85 ± 0.44 to 3.06 ± 0.38 mU/L. In healthy control infants and in those infants with similar functional gastrointestinal disturbances who were treated without MTC, serum PRL levels fell significantly from days 3–4 to days 6–7, serum TSH, triiodothyronine and free thyroxine, however, remained unaltered. It is concluded that dopaminergic inhibitory mechanisms may .be involved in the control of pituitary PRL and TSH release already in the neonatal period.

show abstract

“…While the PRL responses to exercise, arginine and insulin-induced hypoglycemia gave conflicted results, an enhancement of PRL release after TRH and metoclopramide has been reported in all healthy subjects studied (L'Hermite et al 1977;Delitala et al 1978). It was postulated that the greater GH response might reflect the fact that a demand for oxidizable substrates, rather than the less specific factors of stress, is probably the principal stimulus for GH during exercise.…”

Section: Discussionmentioning

confidence: 97%

“…Synthetic pyroglutamyl-histidyl-prolinamide or thyrotropin-releasing hormone (TRH) stimulates secretion of PRL and TSH, and its administration has become established as a useful test of pituitary function in a number of clinical situations (Tashjian et al 1971;Bowers et al 1971;Jacobs et al 1971;Guyda and Friesen 1973;Noel et al 1974;Bremner et al 1977;L'Hermite et al 1977;Delitala et al 1978;Ayalon et al 1979;Kopelman et al 1979). TRH induced a rapid increase in circulating PRL and maximal release was reached within 15 min, earlier than that of TSH release.…”

Section: Discussionmentioning

confidence: 99%

Prolactin response to exercise, metoclopramide and other provocative agents in children

Ijaiya

1980

Eur J Pediatr

View full text Add to dashboard Cite

Metoclopramide (MCP), a derivative of procainamide was compared with exercise, arginine, insulin and thyrotropin releasing hormone (TRH) as a prolactin (PRL) releaser in children. The peak response of plasma PRL after oral administration of MCP was greater than that after strenuous exercise and after i.v. administration of pharmacodynamic agents. Normal PRL and TSH responses were observed after TRH administration in all subjects. Variable PRL responses were seen after exercise and after i.v. administration of arginine and insulin, despite significant growth hormone (GH) release following the administration of these agents. MCP produced no increase in plasma TSH. Metoclopramide may be useful for dynamic testing of PRL release in children. It can be taken orally and is free of side-effects.

show abstract

Thyrotropin, Prolactin and Growth Hormone Response to Synthetic Thyrotropin-Releasing Hormone in Newborn Infants

Cited by 8 publications

References 8 publications

Growth Hormone Responses to Growth Hormone Releasing Factor in Neonates

Growth Hormone Responses to Growth Hormone Releasing Factor in Neonates

Effect of Metoclopramide Treatment on Thyrotropin and Prolactin Levels in Sick Neonates

Prolactin response to exercise, metoclopramide and other provocative agents in children

Contact Info

Product

Resources

About